tbuckley/cabot-search huggingface dataset:
AB0361 The impact of obesity in clinical and ultrasonic activity of tunisian rheumatoid arthritis
Authors: K. ben abdelghani, A. feki, A. fazaa, K. ouenniche, S. miladi, S. kassab, S. chekili, A. laatar, L. zakraoui
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Obesity is one of the most frequent comorbidities among patients with rheumatoid arthritis (RA). It has been proposed as a risk factor of poorer response to treatment and lower likely chance of achieving RA disease remission.<sup>1</sup> <h3>Objectives</h3> The objective of this study was to evaluate the effect of obesity on clinical and musculoskeletal ultrasound (MSUS) disease activity. <h3>Methods</h3> Cross-sectional clinical and laboratory data were collected on 44 RA patients. MSUS assessment of power Doppler (PDUS) and grey scale (GSUS) hypertrophy and effusion was performed on 11 joints of dominant hand (wrist, metacarpalphalangeal 1–5 and proximal interphalgeal 1–5). PDUS and GSUS were scored semi-quantitatively on a scale of 0–3. The max score of the views obtained for each joint was computed and then was theses maximums were summed across all 11joints to obtain total PDUS (range 0–33) and GSUS (range0–33) scores. DAS28/ESR was calculated. Patients were categorised by BMI (kg/m<sup>2</sup>): &lt;25 (group 1), 25–30 (group 2), and &gt;30 (group 3). Demographic, clinical and ultrasonographic characteristics were compared across BMI groups. P values&lt;0.05 were considered statistically significant. <h3>Results</h3> The overall cohort was 88.6% female, 43.2% ACPA positive and 63.6%RF seropositive with a mean age of 53.8 and disease duration of 12.9 years. The mean BMI was 28.6. Eighty two percent of patients were on sDMARD, 18.2% were on Biologics, and 68.2% of patients were on prednisone. There were no significant differences in these characteristics across the BMI categories. The overall median and interquartile ranges (IQR): 4.1 (1.3) for DAS28/ESR, 3.9 (4.1) for GSUS scores and 4 (5.1) for PDUS scores. The disease activity as measure was not significantly different across the BMI groups (p=0.61). Both GSUS and PDUS scores were not significantly different across BMI groups. Concerning GSUS score: the median (IQR) scores was 5.3 (5.4) for group1, 4.4 (4.3) for group2 and 2.6 (2.7) for group3 (p=0.41). For the PDUS scores the median (IQR) scores was 6 (8.6) for group1, 4.3 (4.1) for group2 and 2.3 (2.7) for group3 (p=0.37). There was no statistically significant correlation of BMI with ultrasound scores (r= – 0.19, p=0.2 for GSUS score and r=−0.22, p=0.14 for PDUS score). <h3>Conclusions</h3> Our study didn't proved differences in clinical or ultrasonic disease activity of RA among BMI. This finding doesn't exclude the hypothesis suggesting that obesity is risk factor of refractory RA which requires a larger number of patients to confirm. <h3>Reference</h3> [1] George MD, et al. Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. Ann Rheum Dis 2017;0:1–4. <h3>Disclosure of Interest</h3> None declared
FRI0192 Predictors of severe hip involvement in ankylosing spondylitis: data from national inpatient sample
Authors: P. Karmacharya, D.R. Poudel, P. Shrestha, R. Dhital, J.M. Davis
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Hip involvement in ankylosing spondylitis (AS) is common (24%–36%), leading to worse functional outcomes. While some cases achieve long-term remission, few develop progressive joint destruction with 5%–8% requiring hip replacement. Although studies in the past have looked at factors associated with severe hip involvement, these remain debated. <h3>Objectives</h3> To investigate the factors associated with severe hip disease in patients with AS using a large inpatient US database. <h3>Methods</h3> Using the Nationwide Inpatient Sample (NIS) data from 2009–2011, we identified patients with AS based on International Classification of Diseases, Ninth Revision (ICD-9) code 720.0 (first 5 positions) and identified patients with hip surgery with ICD-9 procedural codes 800.5, 801.5, 802.5, 803.5, 804.5, 807.5, 808.5, 809.5, 812.1, 815.1, 815.2, 815.3 (any position). NIS is the largest publicly available all-payer inpatient care database in the United States, sponsored by Agency for Healthcare Research and Quality as a part of Healthcare Cost and Utilisation Project. Univariate and multivariate binomial logistic regressions were used to derive odds ratio for predictors of hip surgery. Statistical analysis was done using STATA version 13.0 (College Station, TX). <h3>Results</h3> NIS database from 2009–2011 contained 3538 (weighted counts in the whole US population n=17,480) patients with AS. Out of those, 190 (weighted n=934) had hip surgery (5.36%). Multivariate binomial regression analysis after controlling for confounders (table 1) showed male sex (OR 2.52, CI 1.65–3.83, p&lt;0.001) and peripheral enthesopathy (OR 8.64, CI 2.48–30.12, p&lt;0.001) to be significantly associated with hip surgery in AS patients, and an inverse relationship with inflammatory bowel disease (IBD) (OR 0.35, CI 0.16–0.76, p=0.01) was seen. <h3>Conclusions</h3> Our study found male sex and patients with peripheral enthesopathy to have higher odds of severe hip disease requiring surgery among hospitalised AS patients and significantly lower odds with IBD. Previous studies showed an association with age at onset, delay in diagnosis, bilateral involvement, axial/enthesial disease and severe sacroiliitis. Some of these associations could not be analysed in our study due to lack of individual level patient data. Interestingly, epidemiological factors like smoking and obesity which have been linked to severe disease in PsA, were not found to have any significant association. Routine clinical hip exam and radiological imaging might help to identify high-risk patients. Early therapeutic strategies might be indicated for this specific population to prevent severe hip disease and need for hip replacement surgery. <h3>Disclosure of Interest</h3> None declared
AB0178 Suppression of endoplasmic reticulum stress by 4-pba improves the manifestations of murine lupus through modulating regulatory t cells
Authors: Y.J. Choi, E.-K. Lee, J.-H. Jeong, K.M. Kim, C. Lee, M.S. Lee, W.-H. Yoo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Impaired function of regulatory T cells (Treg) contributes to the pathogenesis of systemic lupus erythematosus (SLE). It has been reported that the aberrant responses of T lymphocytes to endoplasmic reticulum (ER) stress in patients with SLE. <h3>Objectives</h3> In the present study, we investigated whether ER stress inhibition through 4-phenylbutyric acid (4-PBA) ameliorates lupus manifestation on experimental lupus model and the effect of ER stress inhibition by 4-PBA on the frequency and function of Treg. <h3>Methods</h3> Murine lupus model were induced with female BALB/c mice at 7 or 8 weeks of age through Toll-like receptor (TLR) agonist 7 treatment for 4 weeks. From the 8th week, the mice were treated with phosphate buffered saline (PBS), 4-PBA (500 mg/kg, three times weekly) and dexamethasone (1 mg/kg, once a day) for 4 weeks. The increment of body weight, spleen weight, anti-double-stranded DNA (anti-dsDNA) antibody titer, serum cytokine level and the pathology of glomerulonephritis were analysed at 12 weeks of age. The population of immune cellular subset including activated T, B lymphocyte and Treg and suppressive functions of Treg were measured. <h3>Results</h3> 4-PBA significantly decreased the level of anti-dsDNA antibodies, serum TNF-α in murine lupus model, and which were comparable with the efficacy of dexamethasone. A significant decrease in accumulation of immunoglobulin, glomerulonephritis score was also observed in 4-PBA-treated and dexamethasone-treated mice compared with vehicle-treated group. ER stress inhibition decreased the activated T and B lymphocytes population of splenocytes, but the population of Treg was not significantly different between vehicle group and 4-PBA group. However, there was the markedly enhanced suppressive capacity of Treg in 4-PBA-treated group. <h3>Conclusions</h3> The results suggest that ER stress inhibition attenuates disease activity in experimental model, especially in nephritis through improving the suppressive capacity of Treg. Thus, reduction of ER stress could be used as a beneficial therapeutic strategy in SLE. <h3>Disclosure of Interest</h3> None declared
Letter to the Editor: Establishing Reliable Pediatric Percentiles of Serum Liver Enzyme Concentrations Cannot Ignore the Employed Methodology
Authors: Mauro Panteghini, Ferruccio Ceriotti
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. To The Editor: We read with interest the paper by Bussler et al. providing new age‐related and sex‐related percentiles for alanine aminotransferase (ALT), aspartate aminotransferase, and γ‐glutamyltransferase in children between 11 months and 16 years.1 Although the potential relevance of the paper is high, its practical significance is diminished because the analytical aspects of the enzyme measurements were not appropriately described by the authors. This shortcoming limits universal application of the results of this study. Universal reference limits for any laboratory test require that there is enough analytical equivalence between the different methods used to measure a given analyte. Despite the availability of internationally agreed reference systems for standardizing enzyme results in clinical samples, the current evidence is that the evaluated enzymes are not rarely measured by nonstandardized methods that give quite differing values.2 A recent assessment of ALT measurements among Canadian laboratories revealed a between‐laboratory coefficient of variation for ALT of 25%, which is likely not compatible with an interchangeability of results from different marketed assays.3 For measuring aminotransferases, almost all manufacturers (including Roche Diagnostics, manufacturing the measuring system employed by the authors) still market assays with or without the addition of pyridoxal‐5‐phosphate (P‐5'‐P) coenzyme. However, it is impossible to compare results obtained by procedures for aminotransferases that do or do not incorporate P‐5'‐P, because the ratio of preformed holoenzyme to apoenzyme differs among individual clinical samples.4 Unfortunately, Bussler et al. did not discuss how their enzyme results comply with the available reference systems by providing data on assay analytical performances during the study period. Consequently, the analytical validity and standardization of their measurements is unknown.
AB0885 Characteristics of juvenile onset hip arthritis in patients with spondyloarthritis
Authors: W. Hamdi, R. Ben Saad, H. Riahi, K. Maatallah, D. Kaffel, T. Bouaziz, L. Ledab, M. Kchir
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Axial spondyloarthritis (AS) is a chronic inflammatory rheumatic disease that affects the axial skeleton. It typically occurs in the late teens or early twenties and rarely in childhood, defining the juvenile onset (JoAS). The adult-onset AS (AoAS) and Juvenile-onset (JoAS) may share many common features including hip involvement. But their impact on function and quality of life may differ. <h3>Objectives</h3> To compare demographic, clinic and functional outcome of patients with hip involvement in JoAS, with that of patients with AoAS <h3>Methods</h3> Cross-sectional study including patients with AS according to the ,<sup>ASAS criteria of 2009</sup> with hip involvement. The juvenile onset of coxitis was defined by an onset before 16 years of age. An analysis of demographic and clinical comparisons between the two groups was performed including HLA B27 status. Mobility spine outcomes were assessed by the Bath AS Metrology Index (BASMI) and radiographic disease severity by the Bath AS Radiology Index (BASRI). <h3>Results</h3> There were 100 AS aged on average 36.4±12,2 years old.<sup>16–69</sup> The sex ratio was 4.6. The mean duration of progression of AS was 10.93±9,89 years [0.5–24]. It was a JoAS in 15 cases. All patients had a hip involvement. The juvenile onset of hip arthritis was associated with male gender (p=0,042), younger age of patient with AS at the time of recruitment (p=0,007), less severe clinical spinal involvement assessed by schober index (p=0,029) and more frequent and severe enthesitis assessed by MASES (p=0,024). Extra-articular manifestations were significantly more frequent in patients with juvenile onset of hip arthritis (p=0,008). Otherwise the comparison of the two groups showed no difference in the presence of uveitis (p=0,407) and pulmonary involvement (p=0,097). HLAB27 antigen was significantly more common in JoAS (p=0,037). BASRI and BASMI as well as ESR and CRP, were comparable between the two groups (p=0,976, p=0, 626, p=1,000, respectively) <h3>Conclusions</h3> Hip involvement is common in the AS, particularly in JoAS. Our study showed that juvenile onset hip arthritis was associated with male gender, less severe spine involvement, enthesitis and the presence of HLA B27. This would help physicians to identify patients at higher risk of developing hip involvement, to enable early diagnosis. <h3>References</h3> [1] Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis JC, Jr. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis. 2008;67(2):233–7. [2] Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum. 2005;53(3):445–51. <h3>Disclosure of Interest</h3> None declared
Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study
Authors: Rohini Radia, Arun Alfred, Matthew P. Collin, Maria H Gilleece, James E Griffin, Ann E. Hunter, Hannah Hunter, Harpreet Kaur, Nandita Khera, Kavita Raj, Emma Das-Gupta, Fiona Louise Dignan, Madan Jagasia
Journal: Blood (2018)
Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
Authors: Peter Hillmen, Andy Rawstron, Kristian Brock, Samuel Munoz Vicente, Francesca Yates, Rebecca Bishop, Donald Macdonald, Christopher Fegan, Alison McCaig, Anna Schuh, Andrew Pettitt, John G. Gribben, Piers E.M. Patten, Stephen Devereux, Adrian Bloor, Christopher P. Fox, Francesco Forconi, Talha Munir
Journal: Blood (2018)
Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
Authors: Valentine Richez, Cécile Gruchet, Stephanie Guidez, Guillemette Fouquet, Isabelle Azais, Geraldine Durand, Vincent Javaugue, Antoine Brigaud, Florent Plasse, Jeremie Diolez, Antoine Machet, Niels Moya, Helene Gardeney, Paul Franques, Arthur Bobin, Anthony Levy, Florence Sabirou, Anthony Bonnin, Celine Dieval, Sylvain Primault, Jocelyn Barrier, Emmanuel Fleck, Sabrina Bouyier, Claire Daras, Isabelle Princet, Delphine Bauwens, Laurence Legros, Jean-Gabriel Fuzibet, Angela Gil, Franck Bridoux, Hervé Avet-Loiseau, Xavier Leleu
Journal: Blood (2018)
AB1315 Medication use among pregnant women with rheumatic diseases in korea based on the national health insurance service-national sample cohort
Authors: M.K. Chung, J. Lee, E.-H. Ha, J.-Y. Shin
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Many rheumatic diseases (RD) predominantly affect women in their reproductive ages. Medication use during pregnancy is an important issue in women with RD since it may affect the health of both fetus and the mother. <h3>Objectives</h3> This study aimed to characterise the status of medication dispensed for Korean women with RD in pre-gestational period and during pregnancy. <h3>Methods</h3> Women aged between 20–44 years and diagnosed as RD and had delivery after the diagnosis of RD were identified from National Health Insurance Service-National Sample Cohort (NHIC-NSC) (2009–2013). Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS) were included as RD. We analysed prevalence of RD related medication including disease-modifying antirheumatic drugs (DMARDs), NSAIDs, and corticosteroids (CSs) dispensed between the pre-gestational periods of 3 months before pregnancy until delivery. We also analysed prevalence of other medications and supplements which are commonly dispensed during pregnancy in women with RD and the age and sex matched controls. <h3>Results</h3> There were 71 deliveries among 1059 women with RD. In RD pregnancies, 54.9% had taken at least 1 RD related medications. The prevalence of DMARDs dispensing during pregnancy was 23.9%, CSs 43.7%, and NSAIDs 38.0% in RD population. Although usage of antibiotics and medication for thyroid diseases during pregnancies were not different between the women with RD and the control, use of vitamin and iron supplements were significantly higher in the women with RD (38.0% vs 13.4%, p&lt;0.0001). <h3>Conclusions</h3> Medications are frequently required during pregnancies of women with RD. RD are a significant burden for pregnant women requiring increased number of medication use. <h3>References</h3> [1] Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810. [2] Palmsten K, Simard JF, Chambers CD, Arkema EV. Medication use among pregnant women with systemic lupus erythematosus and general population comparators. Rheumatology (Oxford). 2017;56(4):561–9. <h3>Disclosure of Interest</h3> None declared
The Human Lung Cell Atlas : A Comprehensive Reference Map for All Cell Types in the Healthy Human Lung
Authors: M. C. Nawijn, J. Rajagopal, G. H. Koppelman, M. Van den Berge, M. J. Rose-Zerilli, J. W. Holloway, J. L. Schultze, P. Barbry, S. A. Teichmann, S. Prabhakar, F. Theis, H. B. Schiller
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
SAT0099 Sarcopenia is associated with joint damage in rheumatoid arthritis: a cross-sectional study
Authors: J.-Z. Lin, Y.-Y. Wang, P.-J. Liu, Y.-Q. Mo, Q.-H. Li, W.-M. Cheng, X.-L. He, L. Dai
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The association of metabolic status with disease characteristics of rheumatoid arthritis (RA) remain controversial. Body composition (BC) instead of body mass index (BMI) has been more and more recommended to assess metabolic status. <h3>Objectives</h3> To investigate the characteristics of BC in RA patients and their association with RA disease characteristics. <h3>Methods</h3> BC was assessed in RA patients and control subjects by bioelectric impedance analysis. Overfat was defined by body fat percentage (BF%) as ≥25% for men and ≥35% for women. Sarcopenia was defined by skeletal muscle mass index (SMMI)≤8.87 kg/m<sup>2</sup> in men and ≤6.42 kg/m<sup>2</sup> in women. Clinical data including disease activity, function and radiographic assessment were collected. <h3>Results</h3> There were 457 RA patients and 1,860 control subjects recruited. In RA patients, there were 17.7%, 58.0%, 20.1% and 4.2% with underweight, normal weight, overweight, or obesity respectively, and 32.4% were overfat, 11.4% with sarcopenia. Comparisons to control subjects in age and gender stratification showed that male RA patients had significantly lower BMI and SMMI with higher percentage of underweight and sarcopenia in almost all age subgroups; female patients had lower SMMI in all age subgroups and lower BMI with higher prevalence of sarcopenia but higher BF% at age ≤30 and 51–60 years (all P&lt;0.05, figure 1). RA patients with sarcopenia had higher rate of functional limitation, higher disease activity indicators and radiographic scores (all P&lt;0.05, table 1). Multivariate logistic regression analyses showed SMMI (<i>OR</i>=0.633, 95%<i>CI</i>: 0.507~0.790, <i>P</i>&lt;0.001) and sarcopenia (<i>OR</i>=2.154, 95%<i>CI</i>: 1.032~4.497, <i>P</i>=0.041) were associated with radiographic joint damage. <h3>Conclusions</h3> This study showed lower SMMI and higher prevalence of sarcopenia in RA patients which were positively associated with joint damage. <h3>Disclosure of Interest</h3> None declared
Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial
Authors: Leonie K. Callaway, H. David McIntyre, Helen L. Barrett, Katie Foxcroft, Anne Tremellen, Barbara E. Lingwood, Jacinta M. Tobin, Shelley Wilkinson, Alka Kothari, Mark Morrison, Peter O’Rourke, Anita Pelecanos, Marloes Dekker Nitert
Journal: Diabetes Care (2019)

OBJECTIVE Given the role of gut microbiota in regulating metabolism, probiotics administered during pregnancy might prevent gestational diabetes mellitus (GDM). This question has not previously been studied in high-risk overweight and obese pregnant women. We aimed to determine whether probiotics (Lactobacillus rhamnosus and Bifidobacterium animalis subspecies lactis) administered from the second trimester in overweight and obese women prevent GDM as assessed by an oral glucose tolerance test (OGTT) at 28 weeks’ gestation. Secondary outcomes included maternal and neonatal complications, maternal blood pressure and BMI, and infant body composition. RESEARCH DESIGN AND METHODS This was a double-blind randomized controlled trial of probiotic versus placebo in overweight and obese pregnant women in Brisbane, Australia. RESULTS The study was completed in 411 women. GDM occurred in 12.3% (25 of 204) in the placebo arm and 18.4% (38 of 207) in the probiotics arm (P = 0.10). At OGTT, mean fasting glucose was higher in women randomized to probiotics (79.3 mg/dL) compared with placebo (77.5 mg/dL) (P = 0.049). One- and two-hour glucose measures were similar. Preeclampsia occurred in 9.2% of women randomized to probiotics compared with 4.9% in the placebo arm (P = 0.09). Excessive weight gain occurred in 32.5% of women in the probiotics arm (55 of 169) compared with 46% in the placebo arm (81 of 176) (P = 0.01). Rates of small for gestational age (&amp;lt;10th percentile) were 2.4% in the probiotics arm (5 of 205) and 6.5% in the placebo arm (13 of 199) (P = 0.042). There were no differences in other secondary outcomes. CONCLUSIONS The probiotics used in this study did not prevent GDM in overweight and obese pregnant women.